ArticleFrontiers in immunology2021
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Early detection of oral squamous cell carcinoma using five tumor-associated autoantibodies and a Naive Bayes-based machine learning model.Scientific reports · 2026Article
- Computational theranostics strategy for pancreatic ductal adenocarcinoma.Molecular diversity · 2026Article
- Organoid in droplet: Production of uniform pancreatic cancer organoids from single cells.Materials today. Bio · 2025Article
- Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer: Mechanisms and Therapeutic Targeting.Protein and peptide letters · 2025Article
- Bioinformatics-based screening of key genes associated with gemcitabine resistance in advanced pancreatic ductal adenocarcinoma.Translational cancer research · 2024Article
- Tetraspanins in digestive‑system cancers: Expression, function and therapeutic potential (Review).Molecular medicine reports · 2024Review
- Effects of transmembrane serine protease 4 on the survival in patients with pancreatic ductal adenocarcinoma undergoing surgery followed by adjuvant chemotherapy.Surgery today · 2024Article
- ESCCPred: a machine learning model for diagnostic prediction of early esophageal squamous cell carcinoma using autoantibody profiles.British journal of cancer · 2024Article
- A Comparison of Tools That Identify Tumor Cells by Inferring Copy Number Variations from Single-Cell Experiments in Pancreatic Ductal Adenocarcinoma.Biomedicines · 2024Article
- Tspan protein family: focusing on the occurrence, progression, and treatment of cancer.Cell death discovery · 2024Review
- Comparative Evaluation of Machine Learning Models for Subtyping Triple-Negative Breast Cancer: A Deep Learning-Based Multi-Omics Data Integration Approach.Journal of Cancer · 2024Article
- Identification of hub genes to determine drug-disease correlation in breast carcinomas.Medical oncology (Northwood, London, England) · 2023Article
- S100P as a potential biomarker for immunosuppressive microenvironment in pancreatic cancer: a bioinformatics analysis and in vitro study.BMC cancer · 2023Article
- EFHD1 expression is correlated with tumor-infiltrating neutrophils and predicts prognosis in gastric cancer.Heliyon · 2023Article
- SDR16C5 promotes proliferation and migration and inhibits apoptosis in pancreatic cancer.Open life sciences · 2023Article
- Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients.Frontiers in immunology · 2023Article
- A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer.Frontiers in oncology · 2023Article
- A novel immunodiagnosis panel for hepatocellular carcinoma based on bioinformatics and the autoantibody-antigen system.Cancer science · 2022Article
- Identification of potential core genes at single-cell level contributing to pathogenesis of pancreatic ductal adenocarcinoma through bioinformatics analysis.Cancer biomarkers : section A of Disease markers · 2022Article
- The immunological characteristics of TSPAN1 expressing B cells in autoimmune hepatitis.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a lethal malignancy with a poor prognosis. This study aims to identify pancreatic cancer-related genes and develop a robust diagnostic model to detect this disease. Weighted gene co-expression network analysis (WGCNA) was used to determine potential hub genes for pancreatic cancer. Their mRNA and protein expression levels were validated through reverse transcription PCR (RT-PCR) and immunohistochemical (IHC). Diagnostic models were developed by eight machine learning algorithms and ten-fold cross-validation. Four hub genes (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.